A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

ClinicalTrials.gov ID: NCT02076399

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02076399. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

Study identification

NCT ID: NCT02076399
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Rigel Pharmaceuticals; Industry
Enrollment: 76 participants

Conditions and interventions

Conditions

Immune Thrombocytopenic Purpura

Interventions

Fostamatinib disodium Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 14, 2014 (Actual)
Primary completion: Apr 21, 2016 (Actual)
Completion: Apr 21, 2016 (Actual)
Last update posted: Feb 12, 2019

2014 – 2016

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Arizona Oncology Associates	Tucson	Arizona	85710	—
University of Southern California	Los Angeles	California	90089	—
Lakeland Regional Cancer Center	Lakeland	Florida	33805-1965	—
Bleeding & Clotting Disorders Institute	Peoria	Illinois	61614	—
Horizon Oncology Research, Inc	Lafayette	Indiana	47905	—
Center for Cancer and Blood Disorders	Bethesda	Maryland	20817	—
Weill Cornell Medical College/New York Presbyterian Hospital	New York	New York	10065	—
Pitt County Memorial Hospital	Greenville	North Carolina	27858	—
Bill Hefner VA Medical Center	Salisbury	North Carolina	28144	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Signal Point Clinical Research Center LLC	Middletown	Ohio	45042	—
University of Utah Health Sciences Center	Salt Lake City	Utah	84132	—
University of Virginia	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02076399, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 12, 2019 · Synced Nov 12, 2026